A new strategy for treating multiple myeloma

Israel’s UB-Therapeutics is developing a novel therapy for the treatment of multiple myeloma. Its proteasome degradation inhibitor is a cyclic peptide that directly targets the degradation pathway of the proteasome – overcoming cancer’s resistance to existing proteasome inhibitors.




This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *